bioRxiv · 10.1101/2021.03.12.435074
α-Helical peptidic scaffolds to target α-synuclein pathogenic species with high affinity and selectivity.
Abstract
-Synuclein aggregation is a key driver of neurodegeneration in Parkinsons disease and related syndromes. Accordingly, obtaining a molecule that targets -synuclein pathogenic assemblies with high affinity and selectivity is a long-pursued objective. Here, we have exploited the biophysical properties of toxic oligomers and amyloid fibrils to identify a family of -helical peptides that bind selectively to these -synuclein species with low nanomolar affinity, without interfering with the monomeric functional protein. This activity is translated into an unprecedented anti-aggregation potency and the ability to abrogate the oligomers toxicity. With a structure-function relationship in hand, we identified a human peptide expressed in the brain and in the gastrointestinal tract with exceptional binding, antiaggregation, and detoxifying properties, which suggests it might play a protective role against synucleinopathies. The chemical entities we describe here represent a new therapeutic paradigm and are promising tools to assist diagnosis by selectively detecting -synuclein pathogenic species in biofluids.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Santos, J., Gracia, P., Navarro, S., Pena-Diaz, S., Pujols, J., Cremades, N., Pallares, I., Ventura, S.. 2021-03-13. α-Helical peptidic scaffolds to target α-synuclein pathogenic species with high affinity and selectivity.. https://doi.org/10.1101/2021.03.12.435074
Cite the original work for its findings. Save a collection to share your selection of sources.